Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 31,000 shares, a drop of 57.5% from the August 15th total of 72,900 shares. Based on an average trading volume of 887,500 shares, the days-to-cover ratio is presently 0.0 days.
Several brokerages recently weighed in on BAYRY. Berenberg Bank dropped their price target on shares of Bayer Aktiengesellschaft from €74.00 ($87.06) to €60.00 ($70.59) and set a “buy” rating on the stock in a research report on Monday, August 9th. AlphaValue lowered shares of Bayer Aktiengesellschaft to a “buy” rating in a research note on Wednesday, August 4th. Credit Suisse Group reiterated a “neutral” rating on shares of Bayer Aktiengesellschaft in a research note on Friday, August 6th. DZ Bank reiterated a “buy” rating on shares of Bayer Aktiengesellschaft in a research note on Wednesday, May 26th. Finally, Kepler Capital Markets reiterated a “buy” rating on shares of Bayer Aktiengesellschaft in a research note on Friday, June 25th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of “Buy” and an average target price of $39.00.
Shares of BAYRY stock opened at $13.48 on Friday. The company has a 50 day moving average of $14.29 and a 200-day moving average of $15.43. The company has a quick ratio of 0.80, a current ratio of 1.16 and a debt-to-equity ratio of 1.20. Bayer Aktiengesellschaft has a 12-month low of $11.65 and a 12-month high of $17.34. The firm has a market cap of $52.97 billion, a P/E ratio of -16.85, a PEG ratio of 3.32 and a beta of 1.27.
Bayer Aktiengesellschaft Company Profile
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents.
See Also: When is a capital gain realized?
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.